Search bioRxiv⌕ Search

Biology subjects

Rokugo, M.

Publications and source records attributed to Rokugo, M..

2 recordsLinked to original sources

Metabolic cell death of labile iron deficiency as a vulnerability of head and neck squamous cancer cells evaded by BACH1

Head and neck squamous cell carcinoma (HNSCC) remains difficult to treat due to the lack of molecularly targeted drugs with high anti-tumor efficacy and safety. To investigate the involvement of the transcription factor BACH1, which is known to promote the metastasis of various cancers, in the malignant properties of HNSCC cells, we examined the effects of BACH1 depletion with short interfering RNAs in human HNSCC cell lines. We found that knockdown of BACH1 induced cell death due to depletion of intracellular labile iron which is not tightly bound to protein. Mitochodrial electron transfer chain activity was severely reduced but efficiently resuced with supplementation of iron in the medium. By combining chromatin immunoprecipitation-sequence and RNA-sequence analyses, we found that BACH1 represses ferritin genes in HNSCC cells. BACH1 knockdown was found to enhance the effect of tipifarnib, a selective inhibitor of farnesyltransferase required for HRAS activation, resulting in efficient inhibition of proliferation of HNSCC cell lines in vitro. These results indicate that BACH1 is essential for maintaining the amount of labile iron in HNSCC cells to evade metabolic cell death of iron deficiency and to proliferate. BACH1 can be a target for conferring Tipifarnib sensitivity to HNSCC cells.

cancer biology↗

Cancer vaccine attenuates carcinogen induced head and neck cancer with impaired early T cell response

Effective T cell immunotherapy requires understanding antigen-specific T cell development during tumorigenesis and immune surveillance. Here, we aimed to examine the dynamics of antigen-specific T cells from tumor initiation through progression in a tobacco carcinogen mimetic, 4-nitroquinoline-1-oxide (4NQO)-induced head and neck carcinogenesis model utilizing genetically engineered K5CreERT/+/ROSAOVA-GFP/p53fl/fl (KOG) mice. Our findings showed that early ovalbumin (OVA) expression via direct lingual tamoxifen (T) did not impact cancer development and survival, by comparing mice with tongue epithelium expressing OVA (KOG/T/OVA+) to those without OVA (KOG/T/OVA-) controlled by doxycycline. This equivalent tumor growth cannot be attributed to the loss of OVA expression. Intriguingly, although OVA-specific T cells were initially generated in tumor-draining lymph nodes (TDLN), they became undetectable 3 weeks after tamoxifen injection. Moreover, therapeutic anti-PD-1 was unable to restore OVA-specific T cells in TDLN and did not yield anti-tumor activity. Remarkably, OVA synthetic long peptide (SLP) vaccine induced OVA-specific T cells in KOG/T/OVA+ mice, and the combination of SLP vaccine and anti-PD-1 significantly reduced tongue tumor burden and prolonged survival. This study highlights the role of impaired endogenous antigen-specific T cell responses in immune resistance in head and neck cancer and the potential of cancer vaccines to improve outcomes.

cancer biology↗